Gut microbiota and metabolites in myasthenia gravis: Early diagnostic biomarkers and therapeutic strategies
- 6 November 2022
- journal article
- review article
- Published by Elsevier in Clinical Immunology
- Vol. 245, 109173
Abstract
No abstract availableKeywords
Funding Information
- Shanxi Medical University (XD1807)
- Shanxi Province Science Foundation for Youths
- Shanxi Province Science and Technology Department (201901D211314)
This publication has 23 references indexed in Scilit:
- Association of CTLA‐4 polymorphisms with increased risks of myasthenia gravisAnnals of Human Genetics, 2018
- Future prospect of faecal microbiota transplantation as a potential therapy in asthmaAllergologia et Immunopathologia, 2018
- Change in gut microbiota for eczema: Implications for novel therapeutic strategiesAllergologia et Immunopathologia, 2018
- Gut microbiota and colorectal cancer: insights into pathogenesis for novel therapeutic strategiesZeitschrift für Gastroenterologie, 2017
- Ocular Myasthenia Gravis: Toward a Risk of Generalization Score and Sample Size Calculation for a Randomized Controlled Trial of Disease ModificationJournal of Neuro-Ophthalmology, 2016
- Myasthenia gravis — autoantibody characteristics and their implications for therapyNature Reviews Neurology, 2016
- Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia GravisNeurotherapeutics, 2016
- Myasthenia gravis: subgroup classification and therapeutic strategiesThe Lancet Neurology, 2015
- Ocular myasthenia gravisCurrent Opinion in Ophthalmology, 2012
- A systematic review of diagnostic studies in myasthenia gravisNeuromuscular Disorders, 2006